Capecitabine plus oxaliplatin (CapeOx) as well as S1 plus oxaliplatin (SOX) are tolerable and effective for HER2 negative advanced gastric cancer (AGC) patients in first line setting
演題番号 : WS102-4
In the Japanese Gastric Cancer Treatment Guideline (4th edition), S1 plus cisplatin (SP) is mentioned the standard (recommendation 1) and capecitabine plus cisplatin (XP), capecitabine plus oxaliplatin (CapeOx) and S1 plus oxaliplatin (SOX) were considered as recommendation 2 for AGC in first line setting. But few reports were existed about the comparison between CapeOx and SOX.
The selection criteria were pathologically proven AGC (HER2 negative or unknown); no previous chemotherapy; performance status 0-2; able to oral intake; and adequate organ functions. The patients in CapeOx group, capecitabine 1,000mg/m2 was given orally twice daily for 14days followed by a 7-day rest; oxaliplatin 130mg/m2 on day1 was given by intravenous infusion. In SOX group, S1 40mg/m2 was given orally twice daily for 21 days followed by a 14-day rest and oxaliplatin 100mg/m2 intravenous infusion on day1.
The analysis covered 25 patients over the period from Apr 2010 to Dec 2015 (SOX: Apr 2010 to Sep 2011, CapeOx: Dec 2014 to Dec 2015). The median age was 67 years (range 30-79); 22 males and 3 females; PS 0/1~2 score 15/10; 12 patients were treated CapeOx and 13 patients were treated SOX. Progression-free survival and overall survival were 6.57 and 11.7 months with CapeOx and 5.28 and 13.3 months with SOX (no significant difference). The rate of grade 3-4 toxicity in CapeOx/SOX were; neutropenia 8%/15%, anemia 8%/8%. The rate of peripheral sensory neuropathy (all grade) in CapeOx/SOX were 67%/69%. There was no treatment death in both groups.
Conclusions: CapeOx as well as SOX are tolerable and effective for HER2 negative AGC patients in first line setting.